Clinical Trial to Evaluate the Efficacy and Safety of Monotherapy Group of HL1113R1 or HL1113R2 Versus HL1113 (Fixed Dose Combination) in Patients With Essential Hypertension and Type II Diabetes Mellitus

NCT07552389 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

228

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Diabete Type 2

Interventions

DRUG: Test group
DRUG: Exploratory test group
DRUG: Control group 1
DRUG: Control group 2

Sponsor

Hanlim Pharm. Co., Ltd.